[18F]3F4AP PET Imaging in Multiple Sclerosis and Healthy Controls

Phase 1, open-label trial of F-18 3F4AP in multiple sclerosis (MS) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoints: Binding of 18-F 3F4AP in the brain of healthy volunteers and multiple sclerosis subjects and Number of participants with adverse events related to tracer administration at 5 years. Started Mar 2021; status: recruiting.